HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients

Homologous recombination deficiency (HRD) testing has been approved by FDA for selecting epithelial ovarian cancer (EOC) patients who may benefit from the first-line poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy. However, the effects of HRD on the clinical outcomes of first-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lei, Gu, Yu, Zhang, Mengpei, Shi, Xiaohua, Li, Zhe, Xu, Xinyun, Sun, Tianqi, Dong, Yu, Xue, Chao, Zhu, Xiaoru, Lv, Ran, Jiao, Kai, Ji, Xuwo, Wang, Li-juan, Zhang, Yang, Liang, Zhiyong, Jin, Ying, Yin, Rutie, Wu, Ming, Liang, Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232447/
https://www.ncbi.nlm.nih.gov/pubmed/37258600
http://dx.doi.org/10.1038/s41698-023-00402-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232447/
https://www.ncbi.nlm.nih.gov/pubmed/37258600
http://dx.doi.org/10.1038/s41698-023-00402-y

Ejemplares similares